Roche Validates In Silico Method to Predict Drug Metabolism, Disease Propensity; Next Up: Toxicity | GenomeWeb

A computational genetic analysis method developed by scientists at Roche has inched a bit closer toward industrial feasibility after the researchers this month published a pair of papers validating the approach.

The two papers — one in Anesthesiology on disease propensity and a second in Nature Biotechnology on drug metabolism — served as proof of concept of the approach, which uses mouse haplotype information to hone in on genetic factors that contribute to strain-specific phenotype differences.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.